Abstract
Amyloid β-derived diffusible ligands (ADDLs) comprise the neurotoxic subset of soluble Aβ1-42 oligomers, now widely considered to be the molecular cause of memory malfunction and neurodegeneration in Alzheimers disease (AD). We have developed a screening cascade which identifies small molecule modulators of ADDL-mediated neurotoxicity. The primary screen involves a fluorescence resonance energy transfer (FRET)-based assay which selects inhibitors of Aβ1-42 oligomer assembly. The identified hits were further characterized by assessing their ability to inhibit the assembly and binding of ADDLs to cultures of primary hippocampal neurons. This approach has led to the identification of a number of small molecules which inhibit ADDL assembly and their subsequent binding to neurons. Here we describe our small molecule discovery efforts to identify ADDL assembly blocker and ADDL binding inhibitors, and to transform validated hits into pre-clinical lead compounds.
Keywords: ADDL, Alzheimer, amyloid, assembly, drug, inhibitor, neuron, oligomer
Current Alzheimer Research
Title: Discovery of ADDL-Targeting Small Molecule Drugs for Alzheimers Disease
Volume: 4 Issue: 5
Author(s): Raymond M. Lowe, Grant A. Krafft, David Summa, William F. Goure, Susan M. Catalano, Sue Zhang, Hsiu-Mei Wu, Lily Ruslim-Litrus, Michele McEntee, Gary C. Look, Catherine M. Hironaka, Lev Igoudin, Walter J. Crosier, Jean-Claude R. Breach, Todd R. Pray, Diana B. Cherbavaz and Jasna Jerecic
Affiliation:
Keywords: ADDL, Alzheimer, amyloid, assembly, drug, inhibitor, neuron, oligomer
Abstract: Amyloid β-derived diffusible ligands (ADDLs) comprise the neurotoxic subset of soluble Aβ1-42 oligomers, now widely considered to be the molecular cause of memory malfunction and neurodegeneration in Alzheimers disease (AD). We have developed a screening cascade which identifies small molecule modulators of ADDL-mediated neurotoxicity. The primary screen involves a fluorescence resonance energy transfer (FRET)-based assay which selects inhibitors of Aβ1-42 oligomer assembly. The identified hits were further characterized by assessing their ability to inhibit the assembly and binding of ADDLs to cultures of primary hippocampal neurons. This approach has led to the identification of a number of small molecules which inhibit ADDL assembly and their subsequent binding to neurons. Here we describe our small molecule discovery efforts to identify ADDL assembly blocker and ADDL binding inhibitors, and to transform validated hits into pre-clinical lead compounds.
Export Options
About this article
Cite this article as:
Lowe M. Raymond, Krafft A. Grant, Summa David, Goure F. William, Catalano M. Susan, Zhang Sue, Wu Hsiu-Mei, Ruslim-Litrus Lily, McEntee Michele, Look C. Gary, Hironaka M. Catherine, Igoudin Lev, Crosier J. Walter, Breach R. Jean-Claude, Pray R. Todd, Cherbavaz B. Diana and Jerecic Jasna, Discovery of ADDL-Targeting Small Molecule Drugs for Alzheimers Disease, Current Alzheimer Research 2007; 4 (5) . https://dx.doi.org/10.2174/156720507783018271
DOI https://dx.doi.org/10.2174/156720507783018271 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Role of Matrix Metalloproteinases in Diabetes Mellitus
Current Topics in Medicinal Chemistry Kinetic Study on the Effects of Extremely Low Frequency Electromagnetic Field on Catalase, Cytochrome P450 and Inducible Nitric Oxide Synthase in Human HaCaT and THP-1 Cell Lines
CNS & Neurological Disorders - Drug Targets Safety of Dipeptidyl Peptidase 4 Inhibitors for Treatment of Type 2 Diabetes
Current Drug Safety Fibrinogen: A Predictor of Vascular Disease
Current Pharmaceutical Design Risk-Benefit Perspectives in COX-2 Blockade
Current Drug Safety Evidence for Altered LRP/RAGE Expression in Alzheimer Lesion Pathogenesis
Current Alzheimer Research Rho Kinase Inhibitors: Potential Treatments for Diabetes and Diabetic Complications
Current Pharmaceutical Design Depression and Anxiety in Patients with COPD: A Focus on Psychological Treatments in Ambulatory Care Settings
Current Respiratory Medicine Reviews A Review of Therapeutic Effects of Curcumin
Current Pharmaceutical Design Amyloid-Beta Peptide 1-42 Causes Microtubule Deregulation through N-methyl-D-aspartate Receptors in Mature Hippocampal Cultures
Current Alzheimer Research Epigallocatechin-3-gallate(EGCG): Mechanisms and the Combined Applications
Combinatorial Chemistry & High Throughput Screening Tolfenamic Acid: A Modifier of the Tau Protein and its Role in Cognition and Tauopathy
Current Alzheimer Research Computational Models of the Hippocampal Region: Implications for Prediction of Risk for Alzheimers Disease in Non-demented Elderly
Current Alzheimer Research Editorial
Current Medical Imaging A Biomarker Combining Imaging and Neuropsychological Assessment for Tracking Early Alzheimer's Disease in Clinical Trials
Current Alzheimer Research Biological Signatures of Alzheimer’s Disease
Current Topics in Medicinal Chemistry Editorial (Thematic Issue: New Therapeutic Bearings for Repositioned Drugs)
Current Topics in Medicinal Chemistry Recent Progress in Pharmacological and Non-Pharmacological Treatment Options of Major Depression
Current Pharmaceutical Design Therapeutic Noninvasive Brain Stimulation in Alzheimer’s Disease
Current Alzheimer Research Obesity and Metabolic Syndrome Affect the Cholinergic Transmission a nd Cognitive Functions
CNS & Neurological Disorders - Drug Targets